Is there a need to identify novel tumour antigens as targets for immunotherapy clinical trials for the removal of minimal residual disease in haematological malignancies?
Authors
Guinn, Barbara-AnnAffiliation
University of BedfordshireIssue Date
2015-07Subjects
tumour antigensimmunotherapy
clinical trials
minimal residual disease
haematologocial malignancies
leukaemia